Literature DB >> 32761149

Applying Lessons Learned From Low-Resource Settings to Prioritize Cancer Care in a Pandemic.

Rebecca J DeBoer1,2, Temidayo A Fadelu3, Lawrence N Shulman4, Katherine Van Loon1,2.   

Abstract

Importance: The coronavirus disease 2019 (COVID-19) pandemic has forced oncology clinicians and administrators in the United States to set priorities for cancer care owing to resource constraints. As oncology practices adapt to a contracted health care system, expertise gained from partnerships in low-resource settings can be used for guidance. This article provides a primer on priority setting in oncology and ethical guidance based on lessons learned from experience with cancer care priority setting in low-resource settings. Observations: Lessons learned from real-world experiences are myriad. First, in the setting of limited resources, a utilitarian approach to maximizing survival benefit should guide decision-making. Second, conflicting principles will often arise among stakeholders and decision makers. Third, fair decision-making procedures should be established to ensure moral legitimacy and accountability. Fourth, proactive safeguards must be implemented to protect vulnerable individuals, or disparities in cancer treatment and outcomes will only widen further. Fifth, communication with patients and families about priority setting decisions should be intentional and standardized. Sixth, moral distress among clinicians must be addressed to avoid burnout during a time when resilience is critical. Conclusions and Relevance: Although the need to triage cancer care may be new to those who underwent training and now practice oncology in high-resource settings, it is familiar for those who practice in low- and middle-income countries. Oncologists in the United States facing unprecedented decisions about prioritization can draw on ethical frameworks and lessons learned from real-world cancer care priority setting in resource-constrained environments.

Entities:  

Mesh:

Year:  2020        PMID: 32761149     DOI: 10.1001/jamaoncol.2020.2976

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN: 2374-2437            Impact factor:   31.777


  5 in total

1.  Misspelled Word in Title.

Authors: 
Journal:  JAMA Oncol       Date:  2020-09-01       Impact factor: 31.777

Review 2.  Interruption of cancer screening services due to COVID-19 pandemic: lessons from previous disasters.

Authors:  Douglas M Puricelli Perin; Tess Christensen; Andrea Burón; Jennifer S Haas; Aruna Kamineni; Nora Pashayan; Linda Rabeneck; Robert Smith; Miriam Elfström; Mireille J M Broeders
Journal:  Prev Med Rep       Date:  2021-05-17

3.  Moral Distress and Resilience Associated with Cancer Care Priority Setting in a Resource-Limited Context.

Authors:  Rebecca J DeBoer; Espérance Mutoniwase; Cam Nguyen; Anita Ho; Grace Umutesi; Eugene Nkusi; Fidele Sebahungu; Katherine Van Loon; Lawrence N Shulman; Cyprien Shyirambere
Journal:  Oncologist       Date:  2021-05-28

Review 4.  The Impact of the COVID-19 Pandemic on Breast Imaging.

Authors:  Phoebe E Freer
Journal:  Radiol Clin North Am       Date:  2020-09-22       Impact factor: 2.303

5.  Association of Clinical Factors and Recent Anti-Cancer Therapy with COVID-19 Severity among Patients with Cancer: A Report from the COVID-19 and Cancer Consortium.

Authors:  P Grivas; A R Khaki; T M Wise-Draper; B French; C Hennessy; C-Y Hsu; Y Shyr; X Li; T K Choueiri; C A Painter; S Peters; B I Rini; M A Thompson; S Mishra; D R Rivera; J D Acoba; M Z Abidi; Z Bakouny; B Bashir; T Bekaii-Saab; S Berg; E H Bernicker; M A Bilen; P Bindal; R Bishnoi; N Bouganim; D W Bowles; A Cabal; P F Caimi; D D Chism; J Crowell; C Curran; A Desai; B Dixon; D B Doroshow; E B Durbin; A Elkrief; D Farmakiotis; A Fazio; L A Fecher; D B Flora; C R Friese; J Fu; S M Gadgeel; M D Galsky; D M Gill; M J Glover; S Goyal; P Grover; S Gulati; S Gupta; S Halabi; T R Halfdanarson; B Halmos; D J Hausrath; J E Hawley; E Hsu; M Huynh-Le; C Hwang; C Jani; A Jayaraj; D B Johnson; A Kasi; H Khan; V S Koshkin; N M Kuderer; D H Kwon; P E Lammers; A Li; A Loaiza-Bonilla; C A Low; M B Lustberg; G H Lyman; R R McKay; C McNair; H Menon; R A Mesa; V Mico; D Mundt; G Nagaraj; E S Nakasone; J Nakayama; A Nizam; N L Nock; C Park; J M Patel; K G Patel; P Peddi; N A Pennell; A J Piper-Vallillo; M Puc; D Ravindranathan; M E Reeves; D Y Reuben; L Rosenstein; R P Rosovsky; S M Rubinstein; M Salazar; A L Schmidt; G K Schwartz; M R Shah; S A Shah; C Shah; J A Shaya; S R K Singh; M Smits; K E Stockerl-Goldstein; D G Stover; M Streckfuss; S Subbiah; L Tachiki; E Tadesse; A Thakkar; M D Tucker; A K Verma; D C Vinh; M Weiss; J T Wu; E Wulff-Burchfield; Z Xie; P P Yu; T Zhang; A Y Zhou; H Zhu; L Zubiri; D P Shah; J L Warner; G dL Lopes
Journal:  Ann Oncol       Date:  2021-03-18       Impact factor: 32.976

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.